Japan’s Nagoya University Establish Bio Venture Company To Develop Arteriosclerosis Drugs
This article was originally published in PharmAsia News
Nagoya City University established the venture company Hyks Laboratories to develop drugs to treat and prevent arteriosclerosis. Utilizing funds from the Japan Science and Technology Agency, the university's school of medicine has been focusing on research and development of a drug to increase blood's high-density lipoproteins count, Based on the research results, the company also plans to partner with pharmaceutical companies to conduct basic research on HDL functions. Cerebral vascular diseases account for one third of the total deaths in Japan and prevention and treatment have become a major topic for medical researchers and pharmaceutical companies. (Click here for more - Japanese language
You may also be interested in...
A package of health proposals intended to build up the EU’s resilience to health threats while strengthening the competitiveness of Europe’s pharmaceutical industry and ensuring access to affordable drugs takes a major step through the legislative process this week.
Hikma has pushed back against a further attempt by Amarin to counter its US generic version of Vascepa, this time via a fresh lawsuit claiming that the generic induces infringement of patents protecting cardiovascular indications for which the brand is approved but which are carved out of the generic label.
The European Medicines Agency will continue working over the Christmas period so that it can complete its assessment of the newly filed marketing applications for BioNTech/Pfizer’s and Moderna’s COVID-19 vaccines as soon possible.